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Although the Nrf2 (nuclear factor-erythroid 2 p45 subunit-related factor 2) regulated expression of
multiple antioxidant and cytoprotective genes through the electrophile responsive element (EpRE) is
well established, interaction of Nrf2/EpRE with Nrf1, a closely-related transcription factor, is less well
understood. Due to either proteolysis or alternative translation, Nrf1 has been found as proteins of
varying size, p120, p95, and p65, which have been described as either activators of EpRE or competitive
inhibitors of Nrf2. We investigated the effect of Nrf1 on EpRE-regulated gene expression using the
catalytic and modiﬁer subunits of glutamate cysteine ligase (GCLC and GCLM) as models and explored
the potential role of Nrf1 in altering their expression in aging and upon chronic exposure to airborne
nano-sized particulate matter (nPM). Nrf1 knockout resulted in the increased expression of GCLC and
GCLM in human bronchial epithelial (HBE1) cells. Overexpression Nrf2 in combination with either p120
or p65 diminished or failed to further increase the GCLC- and GLCM-EpRE luciferase activity. All known
forms of Nrf1 protein, remained unchanged in the lungs of mice with age or in response to nPM. Our
study shows that Nrf1 could inhibit EpRE activity in vitro, whereas the precise role of Nrf1 in vivo
requires further investigations. We conclude that Nrf1 may not be directly responsible for the loss of
Nrf2-dependent inducibility of antioxidant and cytoprotective genes observed in aged animals.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
It has been well established that nuclear factor-erythroid
2 p45 subunit-related factor 2 (Nrf2) plays a key role in the
regulation of many phase II detoxifying genes. Upon activation by
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Open access under CC BY-NC-Ntranslocated into the nucleus, where it binds to the electro-
phile responsive element (EpRE) located in promoters, thereby
regulating the expression of speciﬁc genes, including many of the
proteins categorized as Phase II detoxiﬁcation enzymes. Studies
have demonstrated that besides Nrf2, several other nuclear
proteins also participate in the formation of Nrf2/EpRE complex
and thus are involved in the regulation of these genes, including
small Maf proteins [1], c-Jun [2], CBP [3], Bach1 [4], and c-Myc [5].
Another emerging mechanism of EpRE/Nrf2 regulation is
mediated by a closely related Nrf family member, Nrf1. As summar-
ized in Fig. 1, full-length Nrf1 (p120 Nrf1) binds to the endoplasmic
reticulum (ER) membrane [6] and is apparently subjected to
intramembrane proteolysis to generate nuclear, active Nrf1 (p95
Nrf1) [6–8]. In addition, there is a 23 kDa Nrf1 fragment that appears
to be generated as a result of this proteolytic processing [9]. Another
short form of Nrf1 (p65 Nrf1) is thought to arise from alternative
translation from internal Met codons 321 and 326 that contain a
stronger Kozak sequence, compared to Met1 [10]. The presence of
the DNA-binding domains and the ability to bind to EpRE, whileD license.
Fig. 1. General summary of competitive nature of Nrf1 forms towards Nrf2-mediated transcription. (A) Translation of entire Nrf1 mRNA coding region gives rise to a full-
length Nrf1, migrating with an apparent molecular weight of 95 (non-glycosylated) or 120 kDa (glycosylated). Internal translation, from Met321 and Met326, that possess
much stronger Kozak sequences compared to Met1, is thought to produce short form of Nrf1, migrating with an apparent MW of 65 kDa (p65 Nrf1, [10]).
(B) In the absence of Nrf1, Nrf2 binds to EpRE and activates transcription of its target genes. (C) Full-length Nrf1 binds to the endoplasmic reticulum (ER) membrane,
and possibly undergoes intramembrane proteolysis to generate nuclear p95 Nrf1 and p23 fragment. Once in the nucleus, Nrf1 competes with Nrf2 by recruiting a different
set of co-activator proteins, controlling the transcription of Nrf1-unique set of genes [12]. (D) Short form of Nrf1 still binds to EpRE, but lacks certain transactivation
domains and leads to diminished transcription of EpRE-controlled genes.
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act as a dominant negative inhibitor of the Nrf2/EpRE activity [11].
In line with that, the expression of Nrf2-target genes was increased
in Nrf2/Nrf1 double knock-out mice [12]. However, some studies
demonstrated that Nrf1 is an enhancer instead of repressor of EpRE
signaling [12], raising the concern of the exact role of Nrf1 in EpRE
signaling and phase II gene regulation.
Based on the dissimilar co-activator domains in Nrf1 and Nrf2, it
has been proposed that Nrf1 recruits a different set of EpRE binding
proteins, resulting in Nrf1-unique expression of the EpRE-regulated
genes [12]. Consistent with the inhibitory role of p65 Nrf1, it was
demonstrated that hypoxia-mediated activation of overexpressed
Nrf1 was accompanied by decreased expression of p65 Nrf1 while
full-length Nrf1 was unaffected [9]. This supports the hypothesis that
the abundance of p65 Nrf1 is regulated under different physiological
conditions, presumably to control the extent of the responses to
oxidative stress through the EpRE [11]. However, more studies are
needed to further understand the function and regulation of p65 Nrf1.
In the current study, the role of Nrf1 in EpRE signaling and phase
II gene regulation was explored using the glutamate cysteine ligase
catalytic subunit (GCLC) gene as a model, as it has been shown to be
regulated through EpRE/Nrf2 signaling [13]. Also the expression of
Nrf1 in mice and its response to airborne nanoparticulate matter
(nPM) was investigated as an extension of our previous ﬁnding that
EpRE signaling and nPM-induced GCLC expression was impaired in
middle-aged adult (21-month-old) compared to young (6-month-
old) mice [14]. Evidence from the current study indicates that Nrf1
may work as an EpRE ‘‘repressor’’, but its role in the regulation of
Nrf2/EpRE signaling and the expression of phase II detoxifying
enzymes remains to be explored.Materials and methods
Reagents
Nrf1 siRNAs and antibody (sc-13031) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). M-PER, mammalian
cell and NE-PER nuclear extraction reagents were purchased from
Pierce (Thermo Fisher Scientiﬁc, Waltham, MA). Restriction
enzymes and accompanying buffers were from New England
BioLabs (Ipswich, MA). Lipofectamine 2000 was from Invitrogen
(Carlsbad, CA). Luciferin was from BioShop Canada (Burlington,
ON). The EMSA kit, including biotinylated EpRE probe from
the human glutamate–cysteine ligase, modiﬁer subunit (gclm)
promoter was purchased from (Panomics, Fremont, CA). Lipo-
fectamineTM RNAiMAX Transfection Reagent was from Life Tech-
nologies (Grand Island, NY). The complete protease inhibitor
cocktail tablets and chlorophenol red-b-D-galactopyranoside
(CPRG) were from Roche Diagnostics (Basel, Switzerland). Other
basic chemicals were purchased from Sigma-Aldrich (St. Louis,
MO). All antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA).
Plasmids
N-terminally FLAG-tagged Nrf2 (pPROEX-HTc-Flag3-Nrf2) was
obtained from Addgene (Addgene plasmid 21553 Cambridge, MA)
and has been described previously [15]. Human Nrf1 cDNA was
purchased from mammalian gene collection (accession number
BC010623) and inserted into a modiﬁed pCR3.1 mammalian
expression vector as previously described [9]. The V-5-tagged
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University of California, Irvine and has been described previously
[11]. The GCLC- and GCLM-EpRE-luciferase reporter plasmids
(-3802GCLC 50-luc and -1927GCLM 50-luc) were a kind gift of
Professor Dale A. Dickinson and their construction has been
described elsewhere [16,17].
Quantitative analysis of mRNA
RNA from cells or homogenized animal tissues was extracted
with TriZol Reagent. The total RNA was treated with DNA-free
reagent to remove contaminating DNA. Then RNA was reverse
transcribed and the mRNA contents of GCLC and GCLM were
determined with real-time PCR assays using the protocol
described before [18]. The primers were as following: GCLC, sense
50-ATGGAGGTGCAATTAACAGAC-30, antisense 50-ACTGCATTGC-
CACCTTTGCA-30; GCLM, sense 50-GCTGTATCAGTGGGCACAG-30,
antisense 50-CGCTTGAATGTCAGGAATGC-30; GAPDH, sense 50-
TGGGTGTGAACCATGAGAAG-3, antisense 50-CCATCACGACA-
CAGTTTCC-3.
Cell culture, transient transfection and luciferase reporter assays
HBE1, an immortalized human bronchial epithelial cell line,
was a gift of Dr. James Yankaskas at the University of North
Carolina and were cultured as previously described [19]. Human
embryonic kidney (HEK293A) cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA) and were
grown in DMEM supplemented with 10% horse serum and 3% P/S/
A (300 units/mL penicillin G, sodium salt, 300 mg/mL streptomy-
cin sulfate and 0.75 mg/mL Fungizones in 0.85% saline (P/S/A)) in
a humidiﬁed atmosphere with 5% CO2 at 37 1C. Cells were plated
in 6-well plates at the density of 100,000 cells/mL and approxi-
mately 48 h later, upon becoming at least 70% conﬂuent, were
transiently transfected using Lipofectamine 2000, following the
manufacturer’s protocol. For each well of a 6-well plate, 0.2 ng of
b-galactosidase, 3.0 mg of GCLC EpRE- or GCLM EpRE-luciferase
and 1.0 mg of pCR3.1 (empty vector), Nrf1-FLAG, or p65Nrf1-V5 in
combination with 1.5 or 2.0 mg of FLAG-Nrf2 myc-Nrf2 were used.
Forty-eight hours later, cells were harvested, lysed and lysates
were subjected to luciferase and b-galactosidase assays as pre-
viously described [9].
Gene silencing
Silencing of Nrf1 gene was performed with transient transfec-
tion of siRNAs. Brieﬂy 50 nM of scrambled control or Nrf1 siRNA
was transfected into HBE1 cells at 75% conﬂuence, following the
manual of the siRNA transfection kit (Life Technology). The cells
were collected for assays after 48 h.
Airborne particle collection, mouse exposure and tissue processing
Airborne vehicular trafﬁc particle collection and mouse treat-
ment have been described previously [14,20]. Brieﬂy, nanoparti-
cles were collected with a High-Volume Ultraﬁne Particle Sampler
[21] at 400 L/min in Los Angeles City near the CA-110 Freeway.
This is a considered to be the mix of fresh ambient particles
mostly from vehicular trafﬁc nearby this freeway [22]. The mean
diameter of particles was 60 nm [20]. C57BL/6 male mice
(3 month- and 18 month-old) were treated with re-aerosolized
nanoparticles or ambient air (control) in sealed exposure cham-
bers for 5 h/day, 3 days/week, for 10 weeks. Mice had normal
weight and no signs of respiratory distress. After isoﬂurane
anesthesia, mice were euthanized and the tissue was collected
and stored at 80 1C until processing. For protein extraction, lungtissue was ground in glass homogenizer using 100 mL of ice-cold
CER I reagent from NE-PER Nuclear and Cytoplasmic Extraction
Kit (Thermo Fisher Scientiﬁc, Rockford, IL), supplemented with
protease and phosphatase inhibitors to prepare total protein
lysate, according to the manufacturer’s protocol. Protein determi-
nation was carried out using Bradford assay (BioRad,
Hercules, CA).
Electrophoretic mobility shift assay (EMSA)
For EMSAs, 10–12 mg of protein lysate per reaction was used
following the manufacturer’s protocol (Panomics/Affymetrix,
Santa Clara, CA). Brieﬂy, after adding the labeled probe to the
nuclear extracts, the mixtures were incubated at 15 1C for 45 min
and subjected to the non-denaturing gel electrophoresis for
75 min at 120 V. For immunodepletion experiments, 2 mg of
pre-immune serum (immunoglobulin G, IgG), anti-Nrf1, Nrf2
or Bach1 (sc-13031, sc-13031, and sc-21755) were added to the
reactions and incubated for 2 h at room temperature as pre-
viously described [23].
Immunoblotting
For Western Blotting assay, 10–12.5 mg of protein per sample
was run on the 10% or 12% SDS-PAGE for 1.5 h at 120 V. The
protein was then transferred onto the Immobilon PVDF mem-
brane (Millipore, Bedford, MA) at 180 mA overnight. The mem-
branes were then probed with 5% milk in Tris-Buffered Saline,
Tween-20 (TBST) for 1 h, followed by 1-hour incubations with
primary and secondary antibodies with six ﬁve-minute washes in
between. V5- tagged p65 Nrf1 was visualized using 1; 1,000
dilution of V5 probe (sc-81594), followed by 1:4000 dilution of
(goat anti-rabbit, sc-2004, Santa Cruz). Enhanced chemilumines-
cence substrate (Millipore, Bedford, MA) and Kodak X-Omat blue
ﬁlm (Perkin-Elmer, Waltham, MA) were used to achieve band
visualization. Developed ﬁlm was scanned using a CanoScan LIDE
80 scanner (Canon, Lake Success, NY) and AlphaEaseFC software,
version 3.1.2 (Alpha Innotech/Cell Biosciences, Santa Clara, CA)
was used for band densitometry.
Statistical analyses
In vitro data were analyzed using Student’s t-test. Semi-
quantitative data from mouse samples were analyzed using
non-parametric Mann–Whitney Rank Sum Test calculator, avail-
able at: http://www.holah.karoo.net/Mann-Whitney%20U-test.xls
and the results were conﬁrmed with SigmaPlot 11.0 (Systat
Software, Inc. San Jose, CA, USA).Results
Silencing Nrf1 induces GCLC and GLCM expression
Expression of GCLC and GCLM, both of which are regulated
through Nrf2-EpRE pathway in human bronchial epithelial (HBE1)
cells [19] was used to investigate potential contribution of Nrf1 to
regulation of these genes. The effect of Nrf1 silencing (RNAi) was
examined using real-time quantitative PCR. Nrf1 silencing
resulted in approximately 1.7-fold increase in the GCLC and GCLM
mRNA expression (Fig. 2A). The effectiveness of RNAi silencing
was veriﬁed with Nrf1 immunoblotting (Fig. 2B). In addition to
the forms of Nrf1 discussed here that migrated with an apparent
molecular weight of 120, 95 and 23 kDa, in Fig. 2B, we note a band
at approximately 30 kDa, in accord with what has been described
regarding some other short Nrf1 forms elsewhere [24].
Fig. 2. Nrf1 silencing increased the expression of GCL genes. HBE1 cells were transfected with scramble or Nrf1 RNAi (ﬁnal concentration 50 nM) for 48 h and collected
for assays. (A) mRNA content of GCLC and GCLM in cells transfected with scramble RNAi (c) or Nrf1 RNAi (Nrf1); (B) Western blotting of Nrf1 and GCLC proteins in cells
with/without Nrf1 silencing. N¼3, n, po0.05 compared with control RNAi (c) (Student’s t-test).
Fig. 3. Simultaneous overexpression of Nrf1 and Nrf2 diminishes or fails to further increase EpRE-driven luciferase activity. HEK293 cells were transfected with empty
vector (pCR3.1), p65Nrf1, p120Nrf1 and Nrf2 along with the luciferase reporter vector with the EpRE from GCLC (A) or GCLM (B). b-galactosidase plasmid was used as the
transfection efﬁciency control and the luciferase signal was normalized to b-galactosidase activity. Shown are means7S.E.M. of at least three independent experiments
(nZ3). Asterisks (n) and the number signs (]) indicate statistically signiﬁcant differences in luciferase activity from lysates of cells, co-transfected with Nrf2 and empty
vector pCR3.1 vs. Nrf2 and either p65 or p120 Nrf1 with po0.05 and po0.001, respectively (Student’s t-test). Statistically signiﬁcant difference (po0.05, Student’s t-test)
between mock (pCR3.1) and Nrf2-transfected samples is indicated by.
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to further increase EpRE-driven luciferase activity
We next investigated the involvement of Nrf1 in the regulation
of Nrf2/EpRE activity using EpRE-driven luciferase reporters.
These reporters were made using the functional EpRE sequences
from GCLC (Fig. 3A) and GCLM (Fig. 3B) and expressed in HEK293Acells. Overexpression of either p65 Nrf1, p120 Nrf1 or Nrf2
resulted in the increased activity of both reporters above the
baseline (Fig. 3A and B), conﬁrming their involvement in mediat-
ing EpRE-driven gene expression. Co-transfection of Nrf2 with
either Nrf1 forms resulted in diminished EpRE reporter activity to
the levels achieved by Nrf1 overexpression alone for GCLC
reporter (Fig. 3A) or led to similar result for GCLM reporter,
Fig. 4. Age-dependent alteration in protein binding to the GCLM EpRE. Protein extracts from lung samples of young (6-month-old) and middle-aged (21-month-old) mice
were analyzed for their ability to bind to a biotinylated EpRE from human GCLM promoter with EMSA (gel-shift) assay as described in Materials and methods. (A) Age-
increased EpRE binding. Representative blot and band densitometry results (N¼5);n, p-valueo0.05, (Rank sum test). (B) Immunodepletion experiments to determine
relative contribution of Nrf1, Nrf2, and Bach1 to the probe. Percentage of immunodepletion (compared to IgG) is shown (N¼5); n, p-value¼0.056, n.s., not signiﬁcantly
different (Rank sum test).
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results suggest dominant role of Nrf1 over Nrf2 and that the
former may act as competitive inhibitor of Nrf2/EpRE activity.
Protein binding to the EpRE increases with age
We previously reported that the basal expression level of
phase II detoxifying genes was increased in lungs of middle-
aged adult (21-month-old) compared to young mice (6-month-
old) [14]. To gain insight into the potential role of Nrf1 in this
change of EpRE activity with aging, we measured the binding of
Nrf1 to GCLM EpRE using gel-shift (EMSA) assays. As shown in
Fig. 4A, protein binding to EpRE (manifested as increased band
density) was more prominent in lungs of 21-month-old compared
to that of 6-month-old mice. There was no obvious effect of nPM
exposure notable, except that in the lungs of aged mice no
increased EpRE binding was seen. The two age-inducible bands
represent the EpRE-protein bound complexes as determined in a
separate experiment using non-labeled (‘‘cold’’) EpRE probe (data
not shown) and as conﬁrmed by immunodepletion experiments
discussed below.
Since increased protein binding on EMSA could be due to
increased abundance and/or activity of transcriptional activators
(e.g., Nrf2) or repressors (e.g., Nrf1 and Bach1), immunodepletion
experiments were carried out. All antibodies efﬁciently depleted
the age-inducible EpRE-protein band, but anti-Nrf2 did so with
much lower efﬁciency compared to anti-Bach1 (Fig. 4B), suggesting
greater prevalence of Bach1 at the EpRE complex compared
to Nrf2.
Nrf1 protein expression is unchanged in aged and nPM-treated
animals
Finally, we investigated the effect of age and nPM treatment
on Nrf1 protein levels. We estimated the relative migration of
full-length and short forms of Nrf1 protein using proteasome
inhibitor MG-132, that stabilizes full-length Nrf1 [7,9] and
ectopically-expressed Nrf1 p65 as references (Fig. 5A). Mouse
short form Nrf1 migrated with an apparent molecular weight of
about 7 kDa lower (67 kDa) than human Nrf1 p65 in HEK293A.
Such a difference is consistent with previous reports of mouse
short form Nrf1 migrating about 10 kDa lower than human short
form of Nrf1, as if it were a 55-kDa polypeptide [24] while humanshort form Nrf1 resolves at 65 kDa on SDS-PAGE gel [10]. There
was no difference in the expression of Nrf1 forms between young
and older mice or between unexposed and nPM-exposed mice
(Fig. 5B and C).Discussion
Many studies point to a puzzling observation that the progres-
sion of oxidative stress-related, non-malignant human diseases is
associated with paradoxical decline in the function of Nrf2 as
reviewed elsewhere [25]. It appears that Nrf2 fails to fulﬁll its
cytoprotective function during aging and conditions of elevated
oxidative stress when its activity is most needed [25]. Several
mechanisms exist to precisely regulate Nrf2 activity as reviewed
in [26]. Amongst them is an emerging concept of Nrf1 acting as an
inhibitor of Nrf2-mediated transcription [11,12], presumably to
limit malignant transformations of healthy cells, associated with
Nrf2 overactivation [11,25]. In this study, we tested the hypoth-
esis that Nrf1 may contribute towards previously described
impairment of phase II enzyme induction in response to a
relevant environmental stressor, nPM [14].
In support of our hypothesis, we found that Nrf1 does indeed
appear to act as an inhibitor of Nrf2 in cultured human cells as
judged by the results of RNAi experiments (Fig. 2) and luciferase
reporter assays (Fig. 3). We note that while the latter provided
a conceptually similar conclusion of Nrf2 inhibition by Nrf1,
co-transfection of Nrf2 with either Nrf1 forms resulted in dimin-
ished EpRE reporter activity (Fig. 3A) or to the lack of further
increase (additivity) in the reporter activity (Fig. 3B). Thus, it
appears that both Nrf1 and Nrf2 act as activators of the EpRE, but
in the presence of both Nrf1 and Nrf2, it is Nrf1 that appears to
ultimately determine the magnitude of the EpRE-controlled
reporter activity. This is in accordance to the notion [12] that,
like Nrf2, Nrf1 regulates EpRE-driven gene expression by associa-
tion with co-activators other than those of Nrf2 (Fig. 1).
Unlike other EpRE-binding transcription factors Nrf2 and
Bach1 [14], we also found that the abundance of Nrf1 fragments
remained unchanged in nPM-treated and aged animals (Figs. 4
and 5). This suggests the involvement of other inhibitors (e.g.,
Bach1 whose protein expression was increased in aged, and
even more so, in aged and nPM-treated mice about 2.5- and
3.5-fold, respectively, compared to young, untreated mice) in the
Fig. 5. Nrf1 protein levels remain stable in aged or nPM-treated in mouse lung. Protein extracts from mice, subjected to the ambient air (100% air) or nPM exposure, were
immunoblotted as described in Materials and Methods. (A) HEK293 lysates from cells with overexpressed short (Nrf1 p65) form of Nrf1 or MG-132-treated (to stabilize
full-length Nrf1) cells were immunonblotted to determine the position of Nrf1 forms in mouse samples. (B) Immunoblotting of mice samples. A representative outcome of
six independent experiments is shown. (C) Band densitometry results for Nrf1 immunoblotting (N¼6). No statistically-signiﬁcant difference was found between all four
conditions for all Nrf1 forms (Rank sum test).
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enzymes that we reported recently [14].
Along the same lines, our EMSA results suggest that protein
binding to GCLM EpRE increases with age and the EpRE is primarily
occupied by EpRE inhibitors Bach1 and Nrf1 rather than activator
Nrf2 under basal conditions. This along with increased abundance
of Bach1 in aged animals [14] suggest that increased binding to the
EpRE in aged animals is mainly due to EpRE inhibitors, which could
explain age-dependent loss of inducibility of phase II genes by nPM,
reported by our group earlier [14]. This scenario is reminiscent of
the displacement of Bach1, bound to the heme oxygenase (HO-1)
EpRE and thus inhibiting HO-1 transcription, by heme; this allows
Nrf2 to bind to the EpRE and activate HO-1 transcription to control
heme levels [4].Conclusions
Taken together, there is accumulating evidence that Nrf1 and
especially its short form p65 act as inhibitors of the Nrf2/EpRE
pathway. However, direct contribution of Nrf1 to a physiologically-
relevant modulation of the Nrf2/EpRE pathway is currently enig-
matic. This is the ﬁrst attempt to address this gap in our knowledge.
Our results suggest that Nrf1 does not contribute to age-related
decline in the inducibility of phase II enzymes.
Current understanding of the physiological role of Nrf1 in
the EpRE-mediated gene expression is greatly impaired by the
lack of knowledge on Nrf1 regulation compared to that of Nrf2
(about 50 vs. over 2000 articles up to date, respectively). Potentiallimitations of current attempts to characterize Nrf1 function
appear to involve differences in competition between Nrf1 and
Nrf2 as observed here between cell types and whole lung. These
may result from differences in the partner proteins in binding to
EpRE. Unlike Nrf2, which robustly responds to various elecrer-
ophiles in terms of increased protein stability, there has been, to
the best of our knowledge, only one report of altered protein
expression of Nrf1 in response to a pro-oxidant [27]. In that study,
protein expression of Nrf1 in human keratinocytes increased
dramatically in response to inorganic arsenite while responding
only marginally to known Nrf2 inducers sulforaphane and tert-
butylhydroquinone [27]. This suggests that the function of Nrf1 in
the EpRE gene expression may be manifested by its altered
protein expression only under certain conditions.
It is anticipated that future studies will identify more clearly
deﬁned models to study the function of Nrf1 in the EpRE-directed
gene expression. In addition, Nrf1 regulation at the protein level
needs further clariﬁcation. For instance, immunoprecipitation
followed by mass spectrometry can aid in the identiﬁcation of
the site(s) of proteolytic cleavage of Nrf1 protein and in docu-
menting the suite of Nrf1- and Nrf2-associated co-activators and
inhibitors to explain the competition of Nrf1 with Nrf2 in
mediating expression of the EpRE-driven gene expression.Acknowledgments
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